Mankind Pharma Limited has informed the Exchange regarding a press release dated May 19, 2026, titled "Press Release Q4FY26 & FY26".
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 4.1 pts more than Nifty Midcap 150 and 4.2 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Mankind Pharma reported Q4FY26 revenue of INR 3,443 Cr, up 11.8% YoY with domestic revenue growing 13.4% to INR 2,886 Cr. Adjusted EBITDA margin expanded 400 bps YoY to 27.1% and PAT margin improved 230 bps to 16.2%. Diluted EPS for Q4 was INR 13.4, up 30.3% YoY. For FY26, full-year revenue stood at INR 14,278 Cr (up 17.0% YoY) with exports surging 34.5% to INR 2,061 Cr. However, FY26 PAT declined 3.4% to INR 1,938 Cr with PAT margin compressing 280 bps to 13.6%, and diluted EPS fell 5.7% to INR 46.3. Adjusted EBITDA margin for FY26 was 25.4%, down 50 bps from FY25. Cash flow remained healthy with CFO to EBITDA ratio at 89% in FY26.
Q4 showed strong operational performance with margin expansion and profit growth, but FY26 full-year results reveal margin compression and profit decline despite robust revenue growth, likely due to one-time costs and investment pressures.